Key Highlights
- Shares trading up 0.27% to $59.86 in today's session.
- Trading Volume reached 4.95 million shares.
- Median progression-free survival reached 42 months versus 20 months for the comparison regimen.
- The trial showed a 51% reduction in the risk of disease progression or death.
Phase 3 Study Meets Primary Endpoint With Strong Results
Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical company with a broad oncology and immunology portfolio, announced topline results from its Phase 3 EXCALIBER-RRMM study. The trial tested ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone against a standard three-drug regimen in 800 patients with relapsed or refractory multiple myeloma.
Median Survival More Than Doubles Versus Comparison Regimen
The combination showed a 51% reduction in the risk of disease progression or death, with median progression-free survival of 42 months versus 20 months for the comparison group, meeting the study's main goal with statistical significance. The safety profile was consistent with ZENBEXUS's established data from earlier studies.
Shares Show Modest Reaction to Already-Anticipated Data
Shares were little changed today, with the modest move suggesting the market may have partly priced in the company's recent approvals in this disease area, including an earlier Accelerated Approval and a more recent expanded approval for a related combination.
Outlook: Third-Quarter Results and Patent Cliff in Focus
Investors are looking ahead to the company's third-quarter results later this month, with patent-cliff concerns for some of its older products still a key focus alongside the continued rollout of newer therapies like ZENBEXUS across additional indications.
FAQs
Q: What did Bristol-Myers Squibb announce today?
A: The company announced positive Phase 3 results showing its drug ZENBEXUS, combined with daratumumab and dexamethasone, significantly improved progression-free survival in multiple myeloma.
Q: How much did the trial reduce disease progression risk?
A: The trial showed a 51% reduction in the risk of disease progression or death compared with a standard three-drug regimen.
Q: Why was the stock's reaction relatively muted?
A: Shares moved only slightly, suggesting the market may have already priced in the company's recent approvals in this disease area.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.